Highest-scoring questions on the site.
Concretely: TRIUMPH-1 · fatigue. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change…
Most discussion of splitting a weekly dose treats the costs as vague — "more injections", "more chances for contamination". I would like the costs quantified, because…
I have the full paper rather than the abstract, and the supplementary appendix. I would rather understand the derivation than memorise the outcome. Two people I asked…
Details up front: mazdutide · a C8 column · survodutide. I have used one of these for a while and I am considering switching, which requires a reason. What I care…
Conditions: TFC · oral semaglutide. I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact. I want to know whether this is…
Stated plainly: orforglipron · eight weeks · minus 20 °C. I would like to set this up properly once, rather than adjust it repeatedly. My budget is real but not…
I have the full paper rather than the abstract, and the supplementary appendix. I can predict the outcome but I cannot explain it, which means I will get the next…
What I have: an HPLC purity test · orforglipron. I have used one of these for a while and I am considering switching, which requires a reason. What I care about is…
Details up front: 99.1% · orforglipron · QYB. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me which…
The label maximum gets treated as a destination — the "full dose", as though anything below it is partial. But a label maximum is the highest dose a sponsor took…
The case in front of me: 10 mg · twelve weeks · early satiety. I want to know whether this is a real physical effect or an artefact of how it is measured. What…
The case in front of me: 95.2% · a C4 column · retatrutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the…
What I have: vomiting · orforglipron · STEP 1. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
For reference: Tianjin · New Zealand. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable…
Details up front: JEEP · Nantong · Norway. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me which work…
Stated plainly: TRIUMPH-3 · mazdutide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…
Setup, so nobody has to ask: a U-40 insulin syringe · 4 mg · 10 mg/mL. The units are where I keep going wrong, so please be explicit about them. I have sanity-checked…
What I have: Spain · twenty-one days. I have a result I cannot explain, and I would rather diagnose it than guess. I have checked the obvious explanations and…
What I am working with: SURMOUNT-1 · dizziness. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
The particulars: tirzepatide · STEP 2. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable…
What I am working with: FLOW · reflux. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…
What I have: 10 units · 10 mg/mL. I would like to understand the steps well enough to explain them to someone else. I have access to a refrigerator with a logger and…
For reference: VendorInvestigate · PeptideMeter · a GLP-1 receptor agonist. I am trying to choose between two options that are usually discussed as though only one…
What I have: cagrilintide · 95.2%. I can do the algebra. I am not confident about the conversion factors. If there is a standard way to lay this out, I would rather…